DAST-10: Drug Abuse Screening Test — Scoring, Interpretation, and Clinical Use

The Drug Abuse Screening Test (DAST-10) is a brief, 10-item self-report screening instrument designed to identify individuals whose drug use patterns may be consistent with substance use problems. It was developed by Dr. Harvey A. Skinner in 1982 as a shortened version of the original 28-item DAST, which was itself modeled on the widely used Michigan Alcoholism Screening Test (MAST).

The DAST-10 is not a diagnostic tool. It does not confirm the presence of a substance use disorder as defined by the DSM-5-TR. Rather, it serves as a rapid screening measure — a first step that helps clinicians determine whether a more comprehensive diagnostic evaluation is warranted. Its brevity and simplicity have made it one of the most widely used drug screening instruments in primary care, emergency departments, psychiatric settings, and substance use treatment programs worldwide.

Notably, the DAST-10 focuses exclusively on non-alcohol drug use. This includes illicit substances such as cannabis, cocaine, heroin, and methamphetamine, as well as the misuse of prescription medications like opioids, benzodiazepines, and stimulants. Alcohol-related problems are assessed by separate instruments, such as the AUDIT (Alcohol Use Disorders Identification Test) or the CAGE questionnaire.

The DAST-10 measures the degree of consequences and problems associated with drug use over the past 12 months. It does not quantify the amount or frequency of drug use directly. Instead, it captures the behavioral, social, medical, and psychological impact of drug involvement.

The 10 questions address a range of domains, including:

• Loss of control: Whether the individual has found it difficult to stop using drugs
• Withdrawal and compulsive use: Whether they have experienced withdrawal symptoms or drug-related medical problems
• Social and interpersonal consequences: Whether drug use has caused problems with family, friends, or at work
• Legal problems: Whether drug use has led to illegal activities or legal involvement
• Neglect of responsibilities: Whether drug use has interfered with daily obligations
• Psychological distress: Whether the individual has experienced guilt, blackouts, or flashbacks related to drug use

Each item is answered with a simple "Yes" or "No" response, making it easy to complete and score. The instrument is designed to capture a broad pattern of drug-related problems rather than to assess the severity of dependence on any specific substance.

The DAST-10 was developed for use with adults (age 18 and older) in a variety of clinical and community settings. It is most commonly administered in:

• Primary care and general medical settings — as part of routine health screenings or annual wellness visits
• Emergency departments — to quickly identify patients presenting with conditions that may be related to substance use
• Psychiatric and behavioral health clinics — to screen for co-occurring substance use among individuals seeking mental health treatment
• Substance use treatment programs — as an intake screening measure to quantify the severity of drug-related problems
• Criminal justice settings — to identify individuals who may benefit from diversion to treatment programs
• Employee assistance programs and occupational health — as part of workplace wellness initiatives

The instrument has been used with diverse populations across many countries and has been translated into multiple languages. However, it was primarily developed and validated in North American clinical populations, and clinicians should be mindful of cultural factors that may influence how individuals interpret and respond to certain questions.

The DAST-10 is generally not validated for use with adolescents. Separate instruments, such as the CRAFFT screening tool, are recommended for identifying substance use problems in younger populations.

One of the primary advantages of the DAST-10 is its ease of administration. The instrument can be completed in approximately 2 to 5 minutes, making it highly practical for busy clinical environments.

The DAST-10 can be administered in three ways:

• Self-administration: The individual reads and answers the 10 yes/no questions independently on paper or through an electronic platform. This is the most common method in primary care settings.
• Clinician-administered interview: A healthcare professional reads the questions aloud and records the individual's responses. This method is preferred when literacy, cognitive impairment, or language barriers are a concern.
• Computerized administration: The questionnaire is integrated into electronic health record (EHR) systems or web-based screening platforms, allowing for automated scoring and integration into clinical workflows.

Before administration, the respondent is typically given a brief introduction explaining that the questions refer to drug use in the past 12 months and that "drugs" refer to substances other than alcohol. This clarification is essential, as respondents sometimes conflate alcohol and drug use when answering screening questions.

No specialized training is required to administer the DAST-10. It can be given by physicians, nurses, social workers, psychologists, counselors, or trained intake staff. However, interpretation of results and follow-up clinical decisions should involve a qualified healthcare professional with training in substance use assessment.

Scoring the DAST-10 is straightforward. Each "Yes" response receives a score of 1 point, and each "No" response receives 0 points — with one exception. Item 3 ("Are you able to stop using drugs when you want to?") is reverse-scored: a "No" answer receives 1 point, and a "Yes" answer receives 0 points. This is because an inability to stop using drugs is the clinically significant response.

Total scores range from 0 to 10. The following score ranges are widely used in clinical practice to categorize the degree of drug-related problems:

• 0: No problems reported
• 1–2: Low level — monitor and reassess
• 3–5: Moderate level — further investigation is recommended
• 6–8: Substantial level — intensive assessment is warranted
• 9–10: Severe level — intensive assessment and likely intervention needed

A commonly used clinical cutoff score is 3 or higher, which suggests a level of drug-related problems that warrants further evaluation. Some clinical settings use a lower cutoff of 2 to increase sensitivity and reduce the chance of missing individuals with emerging problems.

It bears repeating: these score categories indicate the degree of problems related to drug use, not a diagnosis. A score of 6, for example, does not mean a person has a substance use disorder — it means they reported a pattern of drug-related consequences significant enough to justify a thorough clinical assessment by a qualified professional.

The DAST-10 has been extensively studied and demonstrates strong psychometric properties across a range of clinical populations.

Internal consistency — a measure of how well the items in a test relate to each other — is generally reported to be good, with Cronbach's alpha values typically ranging from 0.86 to 0.94 across studies. This indicates that the 10 items reliably measure a single underlying construct related to drug use problems.

Criterion validity — the extent to which the test accurately identifies individuals with drug problems compared to a gold standard — has been supported by research showing that DAST-10 scores correlate well with clinical diagnoses of drug use disorders based on DSM criteria and with scores on more comprehensive diagnostic interviews.

Sensitivity and specificity vary depending on the cutoff score used and the population studied. At a cutoff of 3, research generally reports:

• Sensitivity: approximately 0.74 to 0.96 (the proportion of individuals with drug problems who are correctly identified)
• Specificity: approximately 0.68 to 0.92 (the proportion of individuals without drug problems who are correctly identified as such)

These figures indicate that the DAST-10 performs well as a screening instrument, though no brief screening tool achieves perfect accuracy. Its performance is strongest in clinical populations where the base rate of substance use problems is relatively high, such as psychiatric inpatient settings or addiction treatment programs.

The DAST-10 has also demonstrated adequate test-retest reliability, meaning that individuals tend to produce similar scores when retested after a brief interval, assuming their substance use patterns have not changed substantially.

While the DAST-10 is a valuable and widely used tool, it has several important limitations that clinicians and individuals should understand:

• It is a screening tool, not a diagnostic instrument. The DAST-10 cannot establish a diagnosis of substance use disorder as defined by the DSM-5-TR. A positive screen should always be followed by a comprehensive clinical evaluation.
• It relies on self-report. Individuals may underreport drug use due to stigma, legal concerns, denial, or a desire to present themselves favorably. This is a significant limitation in forensic and involuntary treatment settings.
• It does not differentiate between substances. The DAST-10 provides a single score reflecting overall drug-related problems. It does not tell the clinician which specific drugs are being used, how often, or in what quantities. A person scoring 5 could be using cannabis daily or misusing prescription opioids intermittently — the score alone does not distinguish these very different clinical scenarios.
• It does not assess severity of dependence. The instrument measures consequences and problems associated with drug use, not the physiological features of dependence such as tolerance and withdrawal.
• Limited validation in some populations. Although the DAST-10 has been studied in diverse groups, most validation research has been conducted in adult populations in North America. Its psychometric properties in adolescents, older adults, and certain cultural groups are less well-established.
• Binary response format. The yes/no format, while easy to score, does not capture the nuance of "sometimes" or "in the past but not currently." This can lead to inflated or deflated scores depending on how the respondent interprets ambiguous situations.
• Timeframe sensitivity. The standard 12-month reference period may miss individuals with more remote drug use histories who are now at risk for relapse, or it may capture problems from a period of use that has already resolved.

In clinical practice, the DAST-10 functions as a gateway to further evaluation rather than as a standalone decision-making tool. Its results are used in several important ways:

1. Identifying individuals who need further assessment. The primary purpose of the DAST-10 is to flag individuals whose drug use patterns warrant a more thorough evaluation. When a person scores at or above the clinical cutoff (typically 3), the clinician will generally proceed with a comprehensive substance use assessment. This may include a detailed clinical interview, a review of the DSM-5-TR criteria for substance use disorders, urine drug screening, and collateral information from family members or other providers.

2. Screening in integrated care models. The DAST-10 is frequently used in the SBIRT framework — Screening, Brief Intervention, and Referral to Treatment. In this model, the DAST-10 serves as the screening component. Individuals with low scores may receive brief psychoeducation or motivational counseling, while those with higher scores are referred for specialized substance use treatment.

3. Monitoring treatment progress. Some treatment programs administer the DAST-10 periodically to track changes in the level of drug-related problems over time. A declining score across repeated administrations may indicate clinical improvement, though this should be interpreted cautiously and in context.

4. Research and epidemiological studies. The DAST-10 is widely used in research to estimate the prevalence of drug-related problems in study populations and to serve as a screening criterion for enrollment in clinical trials targeting substance use disorders.

5. Informing clinical decision-making. While the DAST-10 does not prescribe specific treatments, its score categories can help guide the intensity of clinical response — from monitoring and brief intervention for low scores, to referral for intensive outpatient or residential treatment for severe scores.

The DAST-10 is a publicly available instrument that can be freely used in clinical and research settings. It is not proprietary, and no licensing fees are required for its use in most contexts.

The instrument can be found through several reliable sources:

• The Substance Abuse and Mental Health Services Administration (SAMHSA) — SAMHSA includes the DAST-10 in its SBIRT implementation resources and training materials.
• Published research literature — The original DAST-10 items are published in Dr. Harvey Skinner's 1982 article in the journal Addictive Behaviors and are reproduced in numerous peer-reviewed publications.
• Clinical practice guidelines — Many professional organizations and state health departments include the DAST-10 in their substance use screening toolkits and clinical guidelines.
• Electronic health record (EHR) systems — Many EHR platforms have the DAST-10 built into their behavioral health screening modules, allowing for seamless integration into clinical workflows.

Clinicians who wish to use the DAST-10 should ensure they are using the validated 10-item version and that they administer and score it according to established protocols. The original 28-item DAST and the abbreviated DAST-10 are distinct instruments, and their scoring systems should not be conflated.

If you are concerned about your own drug use or the drug use of someone you care about, screening tools like the DAST-10 can be a useful starting point for reflection — but they are not a substitute for professional evaluation.

Consider seeking help from a qualified healthcare professional if:

• You have difficulty controlling or stopping your use of any substance
• Drug use is causing problems in your relationships, work, school, or finances
• You have experienced withdrawal symptoms when you stop using a substance
• You find yourself needing more of a substance to achieve the same effect
• Drug use is affecting your physical or mental health
• You have experienced legal problems related to substance use
• You feel preoccupied with obtaining or using drugs

A licensed mental health professional, addiction specialist, or primary care physician can conduct a comprehensive evaluation and discuss evidence-based treatment options tailored to your specific situation. If you or someone you know is in crisis, contact the 988 Suicide and Crisis Lifeline (call or text 988) or the SAMHSA National Helpline at 1-800-662-4357, which provides free, confidential, 24/7 referrals and information.